Simonsen, AH;
Herukka, SK;
Andreasen, N;
Baldeiras, I;
Bjerke, M;
Blennow, K;
Engelborghs, S;
... Waldemar, G; + view all
(2017)
Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia.
Alzheimer's and Dementia
, 13
(3)
pp. 274-284.
10.1016/j.jalz.2016.09.008.
Preview |
Text
Zetterberg_1-s2.0-S1552526016329636-main.pdf - Published Version Download (814kB) | Preview |
Abstract
This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.
| Type: | Article |
|---|---|
| Title: | Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.jalz.2016.09.008 |
| Publisher version: | http://dx.doi.org/10.1016/j.jalz.2016.09.008 |
| Language: | English |
| Additional information: | Copyright © 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) |
| Keywords: | Alzheimer's disease; Biomarkers; CSF; Diagnosis; GRADE; Recommendations |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/1537857 |
Archive Staff Only
 |
View Item |
